Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

Regulatory milestones

Alimera Sciences Inc. (NASDAQ:ALIM) was up $0.56 (12%) to $5.05 last week after the U.K.'s NICE issued draft guidance recommending Iluvien fluocinolone acetonide intravitreal implant for chronic diabetic macular edema (DME) patients considered insufficiently responsive to available therapies and who have had their natural lens replaced with an intraocular lens.

The recommendation, which reverses final guidance issued in January, is contingent on Alimera providing Iluvien at an undisclosed discount under a patient access scheme.

Iluvien has an Oct. 17 PDUFA date in the U.S. Alimera has worldwide rights from pSivida Corp. (NASDAQ:PSDV; ASX:PVA), which was up $0.03 to $3.43 for the week on NASDAQ. In Australia, the stock was up A$0.13 to A$3.62.

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) gained $0.26 (11%) to $2.60 last week after FDA recommended in a complete response letter that the company conduct an additional clinical trial of tivozanib to support approval to treat advanced renal cell carcinoma (RCC). The complete response follows a 13-1 vote by FDA's Oncologic Drugs Advisory

Read the full 1629 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers